ZÁNĚT A JEHO OVLIVNĚNÍ SET

Literatura

Hale L.P., Haynes B.F.: Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CDS, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. Journal of Immunology 149 (12): 3809-3816, 1992.
Impact factor: 6,937 Exp-35

Lindner A., Förster O.: Berichtüber den Einfluβ von Wobenzym auf verschiedene Rattenpfotenödeme. Wissenschaftliche Monographic 1985.

Bodi T.: The Effect of Oral Bromelains on Tissue Permeability to Antibiotics and Pain Response to Bradykinin: Double Studies on Human Subjects 1966. Clinical Medicine 7: (1966).

Guggenbichler J.P.: Einfluβhydrolytischer Enzyme auf Thrombusbildung und Thrombolyse. Die Medizinische Welt 39: 277, 1988.

Leskovar P.: AIDS: Neuartige Therapiekonzepte. Dtsch. Zeitschr. Onkol. 22: 26, 1990.

Desser L., Sakalová A., Závadová E., Holomanova D., Mohr T.: Concentrations of soluble tumor necrosis factor receptors, β2-microglobulin, IL-6 and TNF in serum of multiple myeloma patients after chemotherapy and after combined enzyme + chemotherapy. International Journal of Immunotherapy XIII (3/4): 121-130, 1997.
Impact factor: 0,172 Exp-22

Závadová E., Desser L, Mohr T.: Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation. Cancer Biotherapy 10 (2): 147-152, 1995.
Impact factor: 0,781 Exp-92

Kunze, R., Ransberger, K., Buschmans, E., Stauder, G., Gebauer, F.: The adhesion protein CD44 is modulated by proteolytic enzymes, 2nd Int. Congress on Biological Response Modifiers, San Diego/Ca. 1993 (presented Poster 21).

Nakazawa M., Emancipator S.N., Lamn M.E.: Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis. Journal of Experimental Medicine 164: 1973-1987, 1986.
Impact factor: 14,384 Nefro-19

Steffen C., Menzel J.: Grundlagenuntersuchung zur Enzymtherapie bei Immunkomplexkrankheiten. Wiener klinische Wochenschrift 97 (8): 2-11, 1985. Imun-83


Hlavní stránka Úvod pro odborníky O firmě Kontakty Pomáháme druhým Poradna
Zánět a jeho ovlivnění SET Zvýšení využitelnosti antibiotik proteolytickými enzymy Angiologie, flebologie Diabetologie Gynekologie Chirurgie, traumatologie, ortopedie Imunologie Lymfologie ORL Praktické lékařství Pediatrie Revmatologie Sportovní medicína Stomatologie Urologie Omrzliny Hojení ran Literatura Časopisy s Impact faktorem Ostatní literatura Video prezentace SPC Wobenzym SPC Phlogenzym Napište nám své připomínky a poznatky	ZÁNĚT A JEHO OVLIVNĚNÍ SET Literatura Hale L.P., Haynes B.F.: Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CDS, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. Journal of Immunology 149 (12): 3809-3816, 1992. Impact factor: 6,937 Exp-35 Lindner A., Förster O.: Berichtüber den Einfluβ von Wobenzym auf verschiedene Rattenpfotenödeme. Wissenschaftliche Monographic 1985. Bodi T.: The Effect of Oral Bromelains on Tissue Permeability to Antibiotics and Pain Response to Bradykinin: Double Studies on Human Subjects 1966. Clinical Medicine 7: (1966). Guggenbichler J.P.: Einfluβhydrolytischer Enzyme auf Thrombusbildung und Thrombolyse. Die Medizinische Welt 39: 277, 1988. Leskovar P.: AIDS: Neuartige Therapiekonzepte. Dtsch. Zeitschr. Onkol. 22: 26, 1990. Desser L., Sakalová A., Závadová E., Holomanova D., Mohr T.: Concentrations of soluble tumor necrosis factor receptors, β2-microglobulin, IL-6 and TNF in serum of multiple myeloma patients after chemotherapy and after combined enzyme + chemotherapy. International Journal of Immunotherapy XIII (3/4): 121-130, 1997. Impact factor: 0,172 Exp-22 Závadová E., Desser L, Mohr T.: Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation. Cancer Biotherapy 10 (2): 147-152, 1995. Impact factor: 0,781 Exp-92 Kunze, R., Ransberger, K., Buschmans, E., Stauder, G., Gebauer, F.: The adhesion protein CD44 is modulated by proteolytic enzymes, 2nd Int. Congress on Biological Response Modifiers, San Diego/Ca. 1993 (presented Poster 21). Nakazawa M., Emancipator S.N., Lamn M.E.: Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis. Journal of Experimental Medicine 164: 1973-1987, 1986. Impact factor: 14,384 Nefro-19 Steffen C., Menzel J.: Grundlagenuntersuchung zur Enzymtherapie bei Immunkomplexkrankheiten. Wiener klinische Wochenschrift 97 (8): 2-11, 1985. Imun-83
	Lék pro vnitřní užití. Čtěte pečlivě příbalovou informaci. Inzertní stránky společnosti MUCOS Pharma CZ, s.r.o. - tel: (+420)-267 750 003